Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sunnova Energy International Inc.

0.2202
0.0000
Volume:- -
Turnover:- -
Market Cap:27.54M
PE:-0.07
High:0.2202
Open:0.2202
Low:0.2202
Close:0.2202
52wk High:13.00
52wk Low:0.1529
Shares:125.08M
Float Shares:115.53M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9611
EPS(LYR):-2.9611
ROE:-18.60%
ROA:-1.29%
PB:0.02
PE(LYR):-0.07

Loading ...

Novo Nordisk’s Growth Hormone Study Terminated: Implications for Investors

TIPRANKS
·
Aug 08

Sunnova Receives Court Approval for Asset Sale to Secure Operations Under New Ownership

Reuters
·
Aug 01

Novamarine Expands Portfolio with Tornado Yachts Acquisition

TIPRANKS
·
Jul 29

Novo Nordisk’s New Study on Cagrilintide: A Potential Game-Changer in Obesity Treatment?

TIPRANKS
·
Jul 26

Novo Nordisk’s CagriSema Study: A Potential Game-Changer in Diabetes Treatment

TIPRANKS
·
Jul 24

Novo Nordisk’s New Study Targets Kidney Disease: What Investors Need to Know

TIPRANKS
·
Jul 19

Novo Nordisk’s CagriSema Study: A Potential Game-Changer for Diabetes and Weight Management

TIPRANKS
·
Jul 19

Novo Nordisk’s Compassionate Use of Concizumab: A Game-Changer for Haemophilia Treatment?

TIPRANKS
·
Jul 18

Novo Nordisk Completes Study on New Semaglutide Tablet Formulations

TIPRANKS
·
Jul 18

Novo Nordisk’s Ziltivekimab Study: A Potential Game-Changer in Heart Failure Treatment

TIPRANKS
·
Jul 17

Novo Nordisk’s Promising Phase 3 Study on Sickle Cell Disease Treatment

TIPRANKS
·
Jul 16

Novo Nordisk’s Diabetes Study: A New Era in Blood Sugar Management

TIPRANKS
·
Jul 16

Novo Nordisk’s Mim8 Study: A Potential Game-Changer for Haemophilia A Treatment

TIPRANKS
·
Jul 16

Novo Nordisk’s New Insulin Icodec: A Game Changer in Diabetes Management?

TIPRANKS
·
Jul 12

Sunnova Announces Stalking Horse Agreement with Omnidian for Solar Servicing Platform Amid Chapter 11 Restructuring

Reuters
·
Jul 10

Novo Nordisk’s Semaglutide Study: A Boost for Diabetes and PAD Treatment?

TIPRANKS
·
Jul 10

Novo Nordisk’s Semaglutide Study: A Step Forward in Diabetes and PAD Treatment

TIPRANKS
·
Jul 09

Novo Nordisk’s CagriSema Study: A Potential Game-Changer in Obesity Treatment

TIPRANKS
·
Jul 04

Novo Nordisk’s Bold Step in Tackling Childhood Obesity: A New Study Initiative

TIPRANKS
·
Jun 28

Novo Nordisk’s Promising Sickle Cell Study: A Potential Game-Changer?

TIPRANKS
·
Jun 28